AnaptysBio(FRA) AN6

Market Cap€1.43B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€49.01

+1.28%

+0.62Today

AnaptysBio Financials at a Glance

Market Cap

€1.43B

Revenue (TTM)

€199.80

Net Income (TTM)

-€23.73

EPS (TTM)

-€0.95

P/E Ratio

-50.79

Dividend

€0.00

Beta (Volatility)

-0.13 (Low)

Dividend

€0.00

Beta (Volatility)

-0.13 (Low)

Price

€49.01

Volume

Open

€47.89

Price

€49.01

Volume

Open

€47.89

Previous Close

€49.01

Daily Range

€47.69 - €49.01

52-Week Range

€10.80 - €61.48

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

-0.13 (Low)

Price

€49.01

Volume

Open

€47.89

Previous Close

€49.01

Daily Range

€47.69 - €49.01

52-Week Range

€10.80 - €61.48

Estimated Earnings Date

N/A

AN6 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AnaptysBio

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Industry

Biotechnology

Sector

Health Care

Employees

104

CEO

Daniel R. Faga, MBA

Website

www.anaptysbio.com

AN6 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-111.50%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-1.97%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€1.43B

Shares Outstanding

29.61M

Volume

Avg. Volume

2.864

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

AnaptysBio Performance Analysis

AnaptysBio annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 9,788,060	-81.7%
2023	2023-12-31	EUR 15,869,718	62.1%
2024	2024-12-31	EUR 84,386,410	431.7%
2025	2025-12-31	EUR 207,874,875	146.3%

AnaptysBio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -4.35	144.0%
2023	2023-12-31	EUR -5.62	29.3%
2024	2024-12-31	EUR -4.73	-15.8%
2025	2025-12-31	EUR -0.41	-91.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

€21.84

+0.8%

Gross Profit

€21.32

+0.8%

Gross Margin

97.61%

+1.0%

Market Cap

€1.43B

N/A

Market Cap/Employee

€8.81

N/A

Employees

104

N/A

Net Income

-€45.20

+1.2%

EBITDA

-€29.08

+1.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

€456.37

+10.9%

Total Debt

€240.72

+0.8%

Accounts Receivable

€22.35

+1.3%

Inventory

€0.00

N/A

Long Term Debt

€238.88

+0.8%

Short Term Debt

€1.84

+1.0%

Return on Assets

-7.01%

+0.2%

Return on Invested Capital

-22.68%

+1.0%

Free Cash Flow

-€22.17

+2.2%

Operating Cash Flow

-€22.15

+2.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About AN6

What is the current price of AnaptysBio?

AnaptysBio is trading at €49.01 per share.

What is the 52-week range for AnaptysBio?

Over the past 52 weeks, AnaptysBio has traded between €10.80 and €61.48.

How much debt does AnaptysBio have?

As of the most recent reporting period, AnaptysBio reported total debt of €240.72M.

How much cash does AnaptysBio have on hand?

AnaptysBio reported €215.65M in cash and cash equivalents in its most recent financial results.

What is AnaptysBio’s dividend yield?

AnaptysBio does not currently have a dividend yield.

AnaptysBio(FRA) AN6

AnaptysBio Financials at a Glance

AN6 News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About AnaptysBio

AN6 Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

AnaptysBio Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AN6

What is the current price of AnaptysBio?

What is the 52-week range for AnaptysBio?

How much debt does AnaptysBio have?

How much cash does AnaptysBio have on hand?

What is AnaptysBio’s dividend yield?

Premium Investing Services